MedTrace Logo

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

NCT06235814 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-02-05

No results posted yet for this study

Summary

Ideal surgical extent for differentiated thyroid cancer remains unclear. Routine use of molecular analysis in biopsy-proven thyroid cancer could provide important prognostic information to help guide extent of surgery - thyroid lobectomy versus total thyroidectomy. This is a pilot feasibility study for the use of routine molecular analysis in Bethesda V and VI thyroid cancers, with randomization of the intermediate-molecular risk subgroup to thyroid lobectomy and total thyroidectomy. The investigators hypothesize that patients will 1) agree to preoperative molecular analysis, and 2) 50% of intermediate-risk patients will agree to and follow through with randomization. This will be a pilot study for a future randomized controlled trial (RTC) to compare between the two surgical approaches in intermediate-molecular risk thyroid cancer.

Conditions

  • Papillary Thyroid Cancer

Interventions

PROCEDURE

Molecular Analysis for Thyroid Resection

Protocol for Operative Management based on Molecular Risk Classifier Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below: * Low molecular-risk: thyroid lobectomy * High molecular-risk: total thyroidectomy * Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy Of note, the respective operations for the low and high molecular-risk groups are standard of care.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-19
Primary Completion
2026-01-30
Completion
2026-01-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235814 on ClinicalTrials.gov